Today: 21 May 2026
Browse Category

NYSE:SCHD 3 November 2025 - 27 April 2026

Schwab’s SCHD Dividend ETF Is Near $31 — Why Investors Are Choosing It Over VOO Now

Schwab’s SCHD Dividend ETF Is Near $31 — Why Investors Are Choosing It Over VOO Now

Schwab U.S. Dividend Equity ETF (SCHD) held $88.3 billion in net assets as of April 24, with a 3.34% 30-day SEC yield and 0.060% expense ratio. Vanguard’s S&P 500 ETF (VOO) offered a lower 1.16% yield and 0.03% expense ratio. SCHD’s top holdings included Texas Instruments, UnitedHealth, and Chevron. SCHD traded near its 52-week high above $31 on Monday.
27 April 2026
······
SCHD ETF Nears Highs as Dividend Trade Revives and Early Investors Reach 12.5% Yield on Cost

SCHD ETF Nears Highs as Dividend Trade Revives and Early Investors Reach 12.5% Yield on Cost

SCHD traded near its 52-week high at $31.06 midday Monday, up about 14% year to date, according to TipRanks. Reuters reported the fund drew $4 billion of the $24.1 billion first-quarter inflows into U.S. dividend funds. Schwab lists $87.5 billion in assets and a 3.33% 30-day SEC yield. The fund holds 104 stocks and charges a 0.06% expense ratio.
20 April 2026
···
Schwab U.S. Dividend Equity ETF (SCHD): Latest News, Dividend Outlook and Analyst Forecasts – December 6, 2025

Schwab U.S. Dividend Equity ETF (SCHD): Latest News, Dividend Outlook and Analyst Forecasts – December 6, 2025

Schwab U.S. Dividend Equity ETF (SCHD) closed at $27.71 on December 5, 2025, with $71.5 billion in assets and a 0.06% expense ratio. The fund posted a 1-year return of about -3% but maintains a 10-year annualized return near 11.4%. SCHD saw $137 million in net inflows over the past week. Its SEC yield stands around 3.8%, below the 8% yield of rival JEPI.
7 December 2025
··
5 Dividend ETFs That Could Pay You for Life – One Could Turn $500/Month Into $680,000

5 Dividend ETFs That Could Pay You for Life – One Could Turn $500/Month Into $680,000

The Schwab U.S. Dividend Equity ETF (SCHD) yields about 3.9% annually with a 0.06% fee, while JPMorgan’s JEPI offers an 8.6% yield at a 0.35% expense ratio. As of early November 2025, SCHD trades near $26.50, VYM at $139, and JEPI at $57. Some niche ETFs show yields above 10%, but high payouts like TSLY’s 98% have come with steep losses, including a -34% one-year return.
3 November 2025
····

Stock Market Today

  • Regional Banks Q1 Earnings Review: Merchants Bancorp Vs Peers
    May 20, 2026, 8:58 PM EDT. Regional banks faced mixed Q1 results with share prices down 2.9% on average. Merchants Bancorp (NASDAQ:MBIN), focused on low-risk, government-backed lending, reported $175.2 million in revenue, up 20.1% year on year but missed net interest income estimates. Its stock dropped 9% post-earnings. UMB Financial (NASDAQ:UMBF) outperformed with $744.8 million revenue, up 29.3%, exceeding analyst forecasts by 5.4%. Regional banks benefit from rising interest rates and digital transformation, but challenges from fintech competition, deposit outflows, credit risk, and regulatory costs remain, alongside recent stability concerns in commercial real estate exposure.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop